Suchergebnisse - "TT6HN20MVF"

PubPharm (72)

1

Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue Sarcoma

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2023

von Schöffski, P. | Bahleda, R. | Wagner, A. | +7

2

PDGFRα monoclonal antibody : Assessment of toxicity in juvenile mice administered a murine surrogate antibody of olaratumab

enthalten in: Birth defects research | 2023

von Baracani, R. | Bhaskaran, M. | Davis, S. | +2

3

Fooled by Randomness. The Misleading Effect of Treatment Crossover in Randomized Trials of Therapies with Marginal Treatment Benefit

enthalten in: Cancer investigation | 2022

von Valentí, V. | Jiménez-Fonseca, P. | Msaouel, P. | +2

4

Olaratumab-induced Biomarker Modulation in Sarcomas-Letter

enthalten in: Molecular cancer therapeutics | 2021

von Valenti, V. | Carmona-Bayonas, A. | Jimenez-Fonseca, P. | +1

5

Olaratumab-induced Biomarker Modulation in Sarcomas-Response

enthalten in: Molecular cancer therapeutics | 2021

von Martín-Broto, J. | Peterson, P. | Oakley, G. | +2

6

Accelerated Approval of Anticancer Drugs : Lessons Learned From the Example of Olaratumab

enthalten in: Clinical pharmacology and therapeutics | 2021

von Papachristos, A. | Ratain, M.

7

Interim Analysis of the Phase II Study : Noninferiority Study of Doxorubicin with Upfront Dexrazoxane plus Olaratumab for Advanced or Metastatic Soft-Tissue Sarcoma

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2021

von Van Tine, B. | Hirbe, A. | Oppelt, P. | +15

CommentIn: Clin Cancer Res. 2021 Jul 15;27(14):3809-3811. - PMID 33990361

8

Modern multimodality management of patients with caval leiomyosarcoma : New treatment paradigms and potential molecular insights

enthalten in: Journal of surgical oncology | 2021

von Squires, M. | Politano, S. | Pollock, R. | +2

9

Phase 1 trial of olaratumab monotherapy and in combination with chemotherapy in pediatric patients with relapsed/refractory solid and central nervous system tumors

enthalten in: Cancer medicine | 2021

von Mascarenhas, L. | Ogawa, C. | Laetsch, T. | +12

10

Circulating Tumor Cells and Biomarker Modulation with Olaratumab Monotherapy Followed by Olaratumab plus Doxorubicin : Phase Ib Study in Patients with Soft-Tissue Sarcoma

enthalten in: Molecular cancer therapeutics | 2021

von Martín-Broto, J. | Pousa, A. | Brohl, A. | +12

1
2
3
4
5
6
7
8
Nächster »
[8]